Lv6
1860 积分 2024-11-06 加入
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
1天前
待确认
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1天前
待确认
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
20天前
已完结
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
5个月前
已完结
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
5个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
5个月前
已完结
Management of Cancer Therapy–Associated Oral Mucositis
6个月前
已完结
Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents
6个月前
已完结
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
6个月前
已完结
皖公网安备34019202002308
